Monza-Ares S.R.L.
- Address
- Strada Bulandra Tony Actor Nr. 27 Sectorul 2, 021967 Bucharest, Romania
Digestive System Diseases
The site focuses on inflammatory bowel disorders, primarily Crohn's disease and ulcerative colitis, seeking new ways to achieve lasting symptom control.
- Evaluation of oral and injectable agents for inducing clinical remission
- Assessment of endoscopic response as a marker of mucosal healing
- Long‑term safety and tolerability of novel biologics
- Comparison of emerging therapies with established standards
- Strategies for patients with inadequate response to conventional treatment
Monza‑Ares S.R.L., based in Bucharest, Romania, is conducting 13 trials with a team of seven investigators, advancing care for patients across Europe.
Immune System Diseases
Research at the centre also addresses immune‑mediated mechanisms underlying gut inflammation, aiming to modulate the immune response in moderately to severely active disease states.
- Investigation of targeted immune pathways using small‑molecule inhibitors
- Exploration of combination regimens to enhance immune regulation
- Evaluation of biomarkers that predict therapeutic success
- Studies on the durability of immune‑based treatments over extended periods
- Safety monitoring of immune‑modulating agents in diverse patient populations
The programme supports the broader goal of improving outcomes for patients with immune system disorders, reinforcing the site’s reputation in translational gastro‑immunology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Eli Lilly & Co.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Monza-Ares S.R.L.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Mirikizumab | 3 | Unknown | 2018-09-13 | 2025-02-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.